Prelude Therapeutics is a privately held biopharmaceutical company focused on the discovery and development of new medicines based on breakthroughs in cancer research.


Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with experience in developing cancer medicines to create a next generation cancer drug discovery company.

At Prelude, we apply our advanced understanding of molecular networks of cancer cell biology to identify target mechanisms. Medicinal chemistry and clinical development expertise is leveraged to rapidly advance molecules with optimal pharmacological properties in specific patient populations. We work hand-in-hand with academic powerhouses to push the boundaries of therapeutic possibilities for our patients.